Ranjith Chandrasena, MD

  • 2Articles
  • 13KReads
  • 2015–2022Active
  • 8Collaborators
  • 19Citations

About

Ranjith Chandrasena, MD, is affiliated with the Chatham-Kent Clinical Trials Research Centre in Chatham, Ontario, Canada. The author has published on clinical topics including major depressive disorder and sexual dysfunction, with research focusing on treatments such as quetiapine XR for comorbid depressive and anxiety disorders and nabilone for dementia-associated sexual disinhibition. Chandrasena's work has appeared in Psychiatrist.com between 2015 and 2022, often collaborating with co-authors Angela Paric, Arun V. Ravindran, Daria M. Zajac, Gaby Abraham, and Martha McKay.

Publications

JCP
Quetiapine XR in Comorbid Depression and Anxiety
Original Research

Quetiapine XR in Comorbid Depression and Anxiety

March 21, 2022

Quetiapine is often used off-label for anxiety and as an augmentation agent in treatment-resistant depression. This study evaluated the efficacy and tolerability of quetiapine in augmenting first-line antidepressants for...
, , , et al
PCC
Letter to the Editor

Nabilone and Dementia-Associated Sexual Inhibition

February 19, 2015

A variety of pharmacologic interventions have been utilized to manage behavioral and psychological symptoms of dementia. Is nabilone an effective treatment option for agitation and sexual disinhibition, which are...
, ,

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe